JP2008528700A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008528700A5 JP2008528700A5 JP2007554257A JP2007554257A JP2008528700A5 JP 2008528700 A5 JP2008528700 A5 JP 2008528700A5 JP 2007554257 A JP2007554257 A JP 2007554257A JP 2007554257 A JP2007554257 A JP 2007554257A JP 2008528700 A5 JP2008528700 A5 JP 2008528700A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- methyl
- ylmethoxy
- phenoxy
- acetic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 41
- 125000003545 alkoxy group Chemical group 0.000 claims 28
- 150000001875 compounds Chemical class 0.000 claims 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 16
- -1 substituted Chemical class 0.000 claims 14
- 125000003118 aryl group Chemical group 0.000 claims 13
- 125000001072 heteroaryl group Chemical group 0.000 claims 12
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 12
- 239000003112 inhibitor Substances 0.000 claims 12
- 125000005843 halogen group Chemical group 0.000 claims 11
- 125000002947 alkylene group Chemical group 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 8
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 150000003254 radicals Chemical class 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- 208000032928 Dyslipidaemia Diseases 0.000 claims 6
- 208000002705 Glucose Intolerance Diseases 0.000 claims 6
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 201000009104 prediabetes syndrome Diseases 0.000 claims 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 6
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 5
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 5
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 5
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 4
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims 4
- 201000001320 Atherosclerosis Diseases 0.000 claims 4
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 4
- 102000023984 PPAR alpha Human genes 0.000 claims 4
- 108010015181 PPAR delta Proteins 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 claims 4
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims 3
- 208000011231 Crohn disease Diseases 0.000 claims 3
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 claims 3
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 claims 3
- 206010019280 Heart failures Diseases 0.000 claims 3
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 3
- 206010020772 Hypertension Diseases 0.000 claims 3
- 206010056997 Impaired fasting glucose Diseases 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 3
- 206010022489 Insulin Resistance Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 102000003729 Neprilysin Human genes 0.000 claims 3
- 108090000028 Neprilysin Proteins 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 3
- 108010016731 PPAR gamma Proteins 0.000 claims 3
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims 3
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims 3
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 claims 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 3
- 206010003246 arthritis Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 230000003247 decreasing effect Effects 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 210000003205 muscle Anatomy 0.000 claims 3
- 208000010125 myocardial infarction Diseases 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- 102000005962 receptors Human genes 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- 208000023504 respiratory system disease Diseases 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 208000017520 skin disease Diseases 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- 208000019553 vascular disease Diseases 0.000 claims 3
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 claims 2
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 claims 2
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims 2
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 claims 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims 2
- 125000004863 4-trifluoromethoxyphenyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C([H])C([H])=C1* 0.000 claims 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 2
- 102100038495 Bile acid receptor Human genes 0.000 claims 2
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims 2
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 claims 2
- 102000001267 GSK3 Human genes 0.000 claims 2
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 claims 2
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 2
- 102000002072 Non-Receptor Type 1 Protein Tyrosine Phosphatase Human genes 0.000 claims 2
- 108010015847 Non-Receptor Type 1 Protein Tyrosine Phosphatase Proteins 0.000 claims 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims 2
- 229940100389 Sulfonylurea Drugs 0.000 claims 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims 2
- 108010036928 Thiorphan Proteins 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims 2
- 229960004597 dexfenfluramine Drugs 0.000 claims 2
- XXEPPPIWZFICOJ-UHFFFAOYSA-N diethylpropion Chemical compound CCN(CC)C(C)C(=O)C1=CC=CC=C1 XXEPPPIWZFICOJ-UHFFFAOYSA-N 0.000 claims 2
- 229960004890 diethylpropion Drugs 0.000 claims 2
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 claims 2
- 229960005156 digoxin Drugs 0.000 claims 2
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 claims 2
- 229960003765 fluvastatin Drugs 0.000 claims 2
- 230000004153 glucose metabolism Effects 0.000 claims 2
- 201000001421 hyperglycemia Diseases 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 102000004311 liver X receptors Human genes 0.000 claims 2
- 108090000865 liver X receptors Proteins 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000007170 pathology Effects 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- IKBKZGMPCYNSLU-RGVLZGJSSA-N tegaserod Chemical compound C1=C(OC)C=C2C(/C=N/NC(=N)NCCCCC)=CNC2=C1 IKBKZGMPCYNSLU-RGVLZGJSSA-N 0.000 claims 2
- 229960002876 tegaserod Drugs 0.000 claims 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 229960004699 valsartan Drugs 0.000 claims 2
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims 2
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 claims 1
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 claims 1
- BOOOLEGQBVUTKC-NVQSDHBMSA-N (2e,4e)-3-methyl-5-[(1s,2s)-2-methyl-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)cyclopropyl]penta-2,4-dienoic acid Chemical compound OC(=O)\C=C(/C)\C=C\[C@@H]1C[C@]1(C)C1=CC=C2C(C)(C)CCC(C)(C)C2=C1 BOOOLEGQBVUTKC-NVQSDHBMSA-N 0.000 claims 1
- KVVODNUBDFULSC-XMMPIXPASA-N (2r)-1-[4-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methoxy]phenyl]sulfonyl-2,3-dihydroindole-2-carboxylic acid Chemical compound N=1C(COC=2C=CC(=CC=2)S(=O)(=O)N2C3=CC=CC=C3C[C@@H]2C(O)=O)=C(C)OC=1C1=CC=C(C(F)(F)F)C=C1 KVVODNUBDFULSC-XMMPIXPASA-N 0.000 claims 1
- FONCZICQWCUXEB-RUZDIDTESA-N (2r)-2-[4-(9-bromo-2,3-dimethylbenzo[f][1]benzothiol-4-yl)-2,6-dimethylphenoxy]-3-phenylpropanoic acid Chemical compound C([C@@H](OC1=C(C)C=C(C=C1C)C=1C2=CC=CC=C2C(Br)=C2SC(=C(C2=1)C)C)C(O)=O)C1=CC=CC=C1 FONCZICQWCUXEB-RUZDIDTESA-N 0.000 claims 1
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 claims 1
- DMJWENQHWZZWDF-PKOBYXMFSA-N (6aS,13bR)-11-chloro-7-methyl-5,6,6a,8,9,13b-hexahydronaphtho[1,2-a][3]benzazepin-12-ol Chemical compound CN1CCC2=CC(Cl)=C(O)C=C2[C@H]2C3=CC=CC=C3CC[C@H]12 DMJWENQHWZZWDF-PKOBYXMFSA-N 0.000 claims 1
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 claims 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 claims 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 claims 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims 1
- XMQODGUTLZXUGZ-RPBOFIJWSA-N 2-[(3s)-3-[[1-[(2r)-2-ethoxycarbonyl-4-phenylbutyl]cyclopentanecarbonyl]amino]-2-oxo-4,5-dihydro-3h-1-benzazepin-1-yl]acetic acid Chemical compound C([C@@H](C(=O)OCC)CC1(CCCC1)C(=O)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XMQODGUTLZXUGZ-RPBOFIJWSA-N 0.000 claims 1
- HCELCMNWDQVULJ-UHFFFAOYSA-N 2-[2-methyl-4-[[1-(4-methylphenyl)-5-[4-(trifluoromethoxy)phenyl]-1,2,4-triazol-3-yl]methoxy]phenoxy]acetic acid Chemical compound C1=CC(C)=CC=C1N1C(C=2C=CC(OC(F)(F)F)=CC=2)=NC(COC=2C=C(C)C(OCC(O)=O)=CC=2)=N1 HCELCMNWDQVULJ-UHFFFAOYSA-N 0.000 claims 1
- SXDHIYUQIXNJJU-UHFFFAOYSA-N 2-[2-methyl-4-[[1-(4-methylsulfanylphenyl)-5-[4-(trifluoromethoxy)phenyl]-1,2,4-triazol-3-yl]methoxy]phenoxy]acetic acid Chemical compound C1=CC(SC)=CC=C1N1C(C=2C=CC(OC(F)(F)F)=CC=2)=NC(COC=2C=C(C)C(OCC(O)=O)=CC=2)=N1 SXDHIYUQIXNJJU-UHFFFAOYSA-N 0.000 claims 1
- LPOWHJUORCZPBU-UHFFFAOYSA-N 2-[2-methyl-4-[[1-(4-propan-2-yloxyphenyl)-2-[4-(trifluoromethyl)phenyl]imidazol-4-yl]methoxy]phenoxy]acetic acid Chemical compound C1=CC(OC(C)C)=CC=C1N1C(C=2C=CC(=CC=2)C(F)(F)F)=NC(COC=2C=C(C)C(OCC(O)=O)=CC=2)=C1 LPOWHJUORCZPBU-UHFFFAOYSA-N 0.000 claims 1
- OIEQQEPWBBQJRX-UHFFFAOYSA-N 2-[2-methyl-4-[[1-(4-propan-2-yloxyphenyl)-5-(4-propylphenyl)-1,2,4-triazol-3-yl]methoxy]phenoxy]acetic acid Chemical compound C1=CC(CCC)=CC=C1C1=NC(COC=2C=C(C)C(OCC(O)=O)=CC=2)=NN1C1=CC=C(OC(C)C)C=C1 OIEQQEPWBBQJRX-UHFFFAOYSA-N 0.000 claims 1
- SUWHYTUVRHJMSC-UHFFFAOYSA-N 2-[2-methyl-4-[[1-(4-propan-2-yloxyphenyl)-5-[3-(trifluoromethyl)phenyl]-1,2,4-triazol-3-yl]methoxy]phenoxy]acetic acid Chemical compound C1=CC(OC(C)C)=CC=C1N1C(C=2C=C(C=CC=2)C(F)(F)F)=NC(COC=2C=C(C)C(OCC(O)=O)=CC=2)=N1 SUWHYTUVRHJMSC-UHFFFAOYSA-N 0.000 claims 1
- DOFWVUWRTWZVDR-UHFFFAOYSA-N 2-[2-methyl-4-[[1-(4-propan-2-yloxyphenyl)-5-[4-(trifluoromethoxy)phenyl]-1,2,4-triazol-3-yl]methoxy]phenoxy]acetic acid Chemical compound C1=CC(OC(C)C)=CC=C1N1C(C=2C=CC(OC(F)(F)F)=CC=2)=NC(COC=2C=C(C)C(OCC(O)=O)=CC=2)=N1 DOFWVUWRTWZVDR-UHFFFAOYSA-N 0.000 claims 1
- KKWQXHVKDSCOTP-UHFFFAOYSA-N 2-[2-methyl-4-[[1-(4-propan-2-yloxyphenyl)-5-[4-(trifluoromethyl)phenyl]-1,2,4-triazol-3-yl]methoxy]phenoxy]acetic acid Chemical compound C1=CC(OC(C)C)=CC=C1N1C(C=2C=CC(=CC=2)C(F)(F)F)=NC(COC=2C=C(C)C(OCC(O)=O)=CC=2)=N1 KKWQXHVKDSCOTP-UHFFFAOYSA-N 0.000 claims 1
- IELMPVVJTGVILW-UHFFFAOYSA-N 2-[2-methyl-4-[[1-(4-propan-2-yloxyphenyl)-5-quinolin-3-yl-1,2,4-triazol-3-yl]methoxy]phenoxy]acetic acid Chemical compound C1=CC(OC(C)C)=CC=C1N1C(C=2C=C3C=CC=CC3=NC=2)=NC(COC=2C=C(C)C(OCC(O)=O)=CC=2)=N1 IELMPVVJTGVILW-UHFFFAOYSA-N 0.000 claims 1
- PGKGVXSUBNHBCC-UHFFFAOYSA-N 2-[2-methyl-4-[[1-[4-(trifluoromethoxy)phenyl]-2-[4-(trifluoromethyl)phenyl]imidazol-4-yl]methoxy]phenoxy]acetic acid Chemical compound C1=C(OCC(O)=O)C(C)=CC(OCC=2N=C(N(C=2)C=2C=CC(OC(F)(F)F)=CC=2)C=2C=CC(=CC=2)C(F)(F)F)=C1 PGKGVXSUBNHBCC-UHFFFAOYSA-N 0.000 claims 1
- AKAXCCVXTOUYRB-UHFFFAOYSA-N 2-[2-methyl-4-[[1-[4-(trifluoromethoxy)phenyl]-5-[4-(trifluoromethyl)phenyl]pyrazol-3-yl]methoxy]phenoxy]acetic acid Chemical compound C1=C(OCC(O)=O)C(C)=CC(OCC2=NN(C(C=3C=CC(=CC=3)C(F)(F)F)=C2)C=2C=CC(OC(F)(F)F)=CC=2)=C1 AKAXCCVXTOUYRB-UHFFFAOYSA-N 0.000 claims 1
- JQTIBDDWIXXMAC-UHFFFAOYSA-N 2-[2-methyl-4-[[5-(4-morpholin-4-ylphenyl)-1-[3-(trifluoromethyl)phenyl]pyrazol-3-yl]methoxy]phenoxy]acetic acid Chemical compound C1=C(OCC(O)=O)C(C)=CC(OCC2=NN(C(C=3C=CC(=CC=3)N3CCOCC3)=C2)C=2C=C(C=CC=2)C(F)(F)F)=C1 JQTIBDDWIXXMAC-UHFFFAOYSA-N 0.000 claims 1
- PUWQZYQDCZRZCY-UHFFFAOYSA-N 2-[2-methyl-4-[[5-(4-morpholin-4-ylphenyl)-1-[4-(trifluoromethoxy)phenyl]pyrazol-3-yl]methoxy]phenoxy]acetic acid Chemical compound C1=C(OCC(O)=O)C(C)=CC(OCC2=NN(C(C=3C=CC(=CC=3)N3CCOCC3)=C2)C=2C=CC(OC(F)(F)F)=CC=2)=C1 PUWQZYQDCZRZCY-UHFFFAOYSA-N 0.000 claims 1
- WBARNCRNGAMDLL-UHFFFAOYSA-N 2-[2-methyl-4-[[5-(4-morpholin-4-ylphenyl)-1-[4-(trifluoromethyl)phenyl]pyrazol-3-yl]methoxy]phenoxy]acetic acid Chemical compound C1=C(OCC(O)=O)C(C)=CC(OCC2=NN(C(C=3C=CC(=CC=3)N3CCOCC3)=C2)C=2C=CC(=CC=2)C(F)(F)F)=C1 WBARNCRNGAMDLL-UHFFFAOYSA-N 0.000 claims 1
- VVPSFBPDGOHMSV-UHFFFAOYSA-N 2-[2-methyl-4-[[5-[3-(trifluoromethoxy)phenyl]-1-[3-(trifluoromethyl)phenyl]pyrazol-3-yl]methoxy]phenoxy]acetic acid Chemical compound C1=C(OCC(O)=O)C(C)=CC(OCC2=NN(C(C=3C=C(OC(F)(F)F)C=CC=3)=C2)C=2C=C(C=CC=2)C(F)(F)F)=C1 VVPSFBPDGOHMSV-UHFFFAOYSA-N 0.000 claims 1
- VCHGMDVXWSHDTD-UHFFFAOYSA-N 2-[2-methyl-4-[[5-[3-(trifluoromethoxy)phenyl]-1-[4-(trifluoromethoxy)phenyl]pyrazol-3-yl]methoxy]phenoxy]acetic acid Chemical compound C1=C(OCC(O)=O)C(C)=CC(OCC2=NN(C(C=3C=C(OC(F)(F)F)C=CC=3)=C2)C=2C=CC(OC(F)(F)F)=CC=2)=C1 VCHGMDVXWSHDTD-UHFFFAOYSA-N 0.000 claims 1
- ILWSPFFZVLPXHG-UHFFFAOYSA-N 2-[2-methyl-4-[[5-[3-(trifluoromethoxy)phenyl]-1-[4-(trifluoromethyl)phenyl]pyrazol-3-yl]methoxy]phenoxy]acetic acid Chemical compound C1=C(OCC(O)=O)C(C)=CC(OCC2=NN(C(C=3C=C(OC(F)(F)F)C=CC=3)=C2)C=2C=CC(=CC=2)C(F)(F)F)=C1 ILWSPFFZVLPXHG-UHFFFAOYSA-N 0.000 claims 1
- LWVDEJPRLHDKQT-UHFFFAOYSA-N 2-[2-methyl-4-[[5-naphthalen-2-yl-1-(4-propan-2-yloxyphenyl)-1,2,4-triazol-3-yl]methoxy]phenoxy]acetic acid Chemical compound C1=CC(OC(C)C)=CC=C1N1C(C=2C=C3C=CC=CC3=CC=2)=NC(COC=2C=C(C)C(OCC(O)=O)=CC=2)=N1 LWVDEJPRLHDKQT-UHFFFAOYSA-N 0.000 claims 1
- OPJJPYUJGZPCNI-UHFFFAOYSA-N 2-[4-[[1,2-bis[4-(trifluoromethoxy)phenyl]imidazol-4-yl]methoxy]-2-methylphenoxy]acetic acid Chemical compound C1=C(OCC(O)=O)C(C)=CC(OCC=2N=C(N(C=2)C=2C=CC(OC(F)(F)F)=CC=2)C=2C=CC(OC(F)(F)F)=CC=2)=C1 OPJJPYUJGZPCNI-UHFFFAOYSA-N 0.000 claims 1
- POKXHZZNAGSFHS-UHFFFAOYSA-N 2-[4-[[1,5-bis(4-methoxyphenyl)pyrazol-3-yl]methoxy]-2-methylphenoxy]acetic acid Chemical compound C1=CC(OC)=CC=C1C1=CC(COC=2C=C(C)C(OCC(O)=O)=CC=2)=NN1C1=CC=C(OC)C=C1 POKXHZZNAGSFHS-UHFFFAOYSA-N 0.000 claims 1
- YCSRWRCCYLAAHE-UHFFFAOYSA-N 2-[4-[[1,5-bis[4-(trifluoromethoxy)phenyl]pyrazol-3-yl]methoxy]-2-methylphenoxy]acetic acid Chemical compound C1=C(OCC(O)=O)C(C)=CC(OCC2=NN(C(C=3C=CC(OC(F)(F)F)=CC=3)=C2)C=2C=CC(OC(F)(F)F)=CC=2)=C1 YCSRWRCCYLAAHE-UHFFFAOYSA-N 0.000 claims 1
- ZLQLKAAEEDIBSE-UHFFFAOYSA-N 2-[4-[[1-(4-methoxyphenyl)-2-[4-(trifluoromethoxy)phenyl]imidazol-4-yl]methoxy]-2-methylphenoxy]acetic acid Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(OC(F)(F)F)=CC=2)=NC(COC=2C=C(C)C(OCC(O)=O)=CC=2)=C1 ZLQLKAAEEDIBSE-UHFFFAOYSA-N 0.000 claims 1
- SFQRKXQPAXXBQE-UHFFFAOYSA-N 2-[4-[[1-(4-methoxyphenyl)-2-[4-(trifluoromethyl)phenyl]imidazol-4-yl]methoxy]-2-methylphenoxy]acetic acid Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(=CC=2)C(F)(F)F)=NC(COC=2C=C(C)C(OCC(O)=O)=CC=2)=C1 SFQRKXQPAXXBQE-UHFFFAOYSA-N 0.000 claims 1
- RLGIGJSZGQRVFE-UHFFFAOYSA-N 2-[4-[[1-(4-methoxyphenyl)-5-(4-morpholin-4-ylphenyl)pyrazol-3-yl]methoxy]-2-methylphenoxy]acetic acid Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(=CC=2)N2CCOCC2)=CC(COC=2C=C(C)C(OCC(O)=O)=CC=2)=N1 RLGIGJSZGQRVFE-UHFFFAOYSA-N 0.000 claims 1
- WJQIKKNIZNWKOV-UHFFFAOYSA-N 2-[4-[[1-(4-methoxyphenyl)-5-[3-(trifluoromethoxy)phenyl]pyrazol-3-yl]methoxy]-2-methylphenoxy]acetic acid Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=C(OC(F)(F)F)C=CC=2)=CC(COC=2C=C(C)C(OCC(O)=O)=CC=2)=N1 WJQIKKNIZNWKOV-UHFFFAOYSA-N 0.000 claims 1
- KRHWPCDRGIZWSR-UHFFFAOYSA-N 2-[4-[[1-(4-methoxyphenyl)-5-[4-(trifluoromethoxy)phenyl]pyrazol-3-yl]methoxy]-2-methylphenoxy]acetic acid Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(OC(F)(F)F)=CC=2)=CC(COC=2C=C(C)C(OCC(O)=O)=CC=2)=N1 KRHWPCDRGIZWSR-UHFFFAOYSA-N 0.000 claims 1
- PNNIKAIQYCDQRM-UHFFFAOYSA-N 2-[4-[[1-(4-methoxyphenyl)-5-[4-(trifluoromethyl)phenyl]pyrazol-3-yl]methoxy]-2-methylphenoxy]acetic acid Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(=CC=2)C(F)(F)F)=CC(COC=2C=C(C)C(OCC(O)=O)=CC=2)=N1 PNNIKAIQYCDQRM-UHFFFAOYSA-N 0.000 claims 1
- GSKAJEDGAIMMMW-UHFFFAOYSA-N 2-[4-[[1-(6-methoxypyridin-3-yl)-2-[4-(trifluoromethoxy)phenyl]imidazol-4-yl]methoxy]-2-methylphenoxy]acetic acid Chemical compound C1=NC(OC)=CC=C1N1C(C=2C=CC(OC(F)(F)F)=CC=2)=NC(COC=2C=C(C)C(OCC(O)=O)=CC=2)=C1 GSKAJEDGAIMMMW-UHFFFAOYSA-N 0.000 claims 1
- PJAJGCKNLYANOZ-UHFFFAOYSA-N 2-[4-[[1-(6-methoxypyridin-3-yl)-2-[4-(trifluoromethyl)phenyl]imidazol-4-yl]methoxy]-2-methylphenoxy]acetic acid Chemical compound C1=NC(OC)=CC=C1N1C(C=2C=CC(=CC=2)C(F)(F)F)=NC(COC=2C=C(C)C(OCC(O)=O)=CC=2)=C1 PJAJGCKNLYANOZ-UHFFFAOYSA-N 0.000 claims 1
- MYJQQAPTWXMKTA-UHFFFAOYSA-N 2-[4-[[1-(6-methoxypyridin-3-yl)-5-[4-(trifluoromethoxy)phenyl]pyrazol-3-yl]methoxy]-2-methylphenoxy]acetic acid Chemical compound C1=NC(OC)=CC=C1N1C(C=2C=CC(OC(F)(F)F)=CC=2)=CC(COC=2C=C(C)C(OCC(O)=O)=CC=2)=N1 MYJQQAPTWXMKTA-UHFFFAOYSA-N 0.000 claims 1
- FSOLVLNCKJWTIV-UHFFFAOYSA-N 2-[4-[[1-(6-methoxypyridin-3-yl)-5-[4-(trifluoromethyl)phenyl]-1,2,4-triazol-3-yl]methoxy]-2-methylphenoxy]acetic acid Chemical compound C1=NC(OC)=CC=C1N1C(C=2C=CC(=CC=2)C(F)(F)F)=NC(COC=2C=C(C)C(OCC(O)=O)=CC=2)=N1 FSOLVLNCKJWTIV-UHFFFAOYSA-N 0.000 claims 1
- VBHQRTSHDWFRAY-UHFFFAOYSA-N 2-[4-[[2-(4-methoxyphenyl)-1-[4-(trifluoromethoxy)phenyl]imidazol-4-yl]methoxy]-2-methylphenoxy]acetic acid Chemical compound C1=CC(OC)=CC=C1C1=NC(COC=2C=C(C)C(OCC(O)=O)=CC=2)=CN1C1=CC=C(OC(F)(F)F)C=C1 VBHQRTSHDWFRAY-UHFFFAOYSA-N 0.000 claims 1
- MWUIMKKTKXWRLW-UHFFFAOYSA-N 2-[4-[[2-(4-methoxyphenyl)-1-[4-(trifluoromethyl)phenyl]imidazol-4-yl]methoxy]-2-methylphenoxy]acetic acid Chemical compound C1=CC(OC)=CC=C1C1=NC(COC=2C=C(C)C(OCC(O)=O)=CC=2)=CN1C1=CC=C(C(F)(F)F)C=C1 MWUIMKKTKXWRLW-UHFFFAOYSA-N 0.000 claims 1
- RBWNFKFFYBFDIQ-UHFFFAOYSA-N 2-[4-[[5-(4-methoxyphenyl)-1-[3-(trifluoromethyl)phenyl]pyrazol-3-yl]methoxy]-2-methylphenoxy]acetic acid Chemical compound C1=CC(OC)=CC=C1C1=CC(COC=2C=C(C)C(OCC(O)=O)=CC=2)=NN1C1=CC=CC(C(F)(F)F)=C1 RBWNFKFFYBFDIQ-UHFFFAOYSA-N 0.000 claims 1
- VVISMZITQROBPQ-UHFFFAOYSA-N 2-[4-[[5-(4-methoxyphenyl)-1-[4-(trifluoromethoxy)phenyl]-1,2,4-triazol-3-yl]methoxy]-2-methylphenoxy]acetic acid Chemical compound C1=CC(OC)=CC=C1C1=NC(COC=2C=C(C)C(OCC(O)=O)=CC=2)=NN1C1=CC=C(OC(F)(F)F)C=C1 VVISMZITQROBPQ-UHFFFAOYSA-N 0.000 claims 1
- ZWOLIDUIHJKKRH-UHFFFAOYSA-N 2-[4-[[5-(4-methoxyphenyl)-1-[4-(trifluoromethoxy)phenyl]pyrazol-3-yl]methoxy]-2-methylphenoxy]acetic acid Chemical compound C1=CC(OC)=CC=C1C1=CC(COC=2C=C(C)C(OCC(O)=O)=CC=2)=NN1C1=CC=C(OC(F)(F)F)C=C1 ZWOLIDUIHJKKRH-UHFFFAOYSA-N 0.000 claims 1
- JTNDASNKLVYTLX-UHFFFAOYSA-N 2-[4-[[5-(4-methoxyphenyl)-1-[4-(trifluoromethyl)phenyl]pyrazol-3-yl]methoxy]-2-methylphenoxy]acetic acid Chemical compound C1=CC(OC)=CC=C1C1=CC(COC=2C=C(C)C(OCC(O)=O)=CC=2)=NN1C1=CC=C(C(F)(F)F)C=C1 JTNDASNKLVYTLX-UHFFFAOYSA-N 0.000 claims 1
- PVMQHBPQIBZYFU-UHFFFAOYSA-N 2-[4-[[5-(4-tert-butylphenyl)-1-(4-propan-2-yloxyphenyl)-1,2,4-triazol-3-yl]methoxy]-2-methylphenoxy]acetic acid Chemical compound C1=CC(OC(C)C)=CC=C1N1C(C=2C=CC(=CC=2)C(C)(C)C)=NC(COC=2C=C(C)C(OCC(O)=O)=CC=2)=N1 PVMQHBPQIBZYFU-UHFFFAOYSA-N 0.000 claims 1
- PLBURMPBQJBUHN-UHFFFAOYSA-N 2-[4-[[5-[1-(4-fluorophenyl)-5-methylpyrazol-4-yl]-1-(4-propan-2-yloxyphenyl)-1,2,4-triazol-3-yl]methoxy]-2-methylphenoxy]acetic acid Chemical compound C1=CC(OC(C)C)=CC=C1N1C(C2=C(N(N=C2)C=2C=CC(F)=CC=2)C)=NC(COC=2C=C(C)C(OCC(O)=O)=CC=2)=N1 PLBURMPBQJBUHN-UHFFFAOYSA-N 0.000 claims 1
- FWWOWPGPERBCNJ-UHFFFAOYSA-N 2-hydroxy-4-(2-hydroxyethoxy)-4-oxobutanoic acid Chemical compound OCCOC(=O)CC(O)C(O)=O FWWOWPGPERBCNJ-UHFFFAOYSA-N 0.000 claims 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 claims 1
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 claims 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 claims 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- NKOHRVBBQISBSB-UHFFFAOYSA-N 5-[(4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(O)=CC=C1CC1C(=O)NC(=O)S1 NKOHRVBBQISBSB-UHFFFAOYSA-N 0.000 claims 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 claims 1
- VNACOBVZDCLAEV-GXKRWWSZSA-N 6-[2-[[2-[(2s)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino]ethylamino]pyridine-3-carbonitrile;dihydrochloride Chemical compound Cl.Cl.N1([C@@H](CCC1)C#N)C(=O)CNCCNC1=CC=C(C#N)C=N1 VNACOBVZDCLAEV-GXKRWWSZSA-N 0.000 claims 1
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 claims 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 claims 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 claims 1
- UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical compound COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 claims 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 1
- 229940123413 Angiotensin II antagonist Drugs 0.000 claims 1
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 claims 1
- 229940123208 Biguanide Drugs 0.000 claims 1
- 208000032841 Bulimia Diseases 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- 239000002083 C09CA01 - Losartan Substances 0.000 claims 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 claims 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 claims 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 229940122820 Cannabinoid receptor antagonist Drugs 0.000 claims 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims 1
- 229920001268 Cholestyramine Polymers 0.000 claims 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 claims 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 claims 1
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 claims 1
- JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 claims 1
- 108010061435 Enalapril Proteins 0.000 claims 1
- 108010011459 Exenatide Proteins 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 108010046163 Glycogen Phosphorylase Proteins 0.000 claims 1
- 102000007390 Glycogen Phosphorylase Human genes 0.000 claims 1
- 208000003577 HIV wasting syndrome Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 229940122199 Insulin secretagogue Drugs 0.000 claims 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 1
- 102000016267 Leptin Human genes 0.000 claims 1
- 108010092277 Leptin Proteins 0.000 claims 1
- 108010007859 Lisinopril Proteins 0.000 claims 1
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 claims 1
- 102000029749 Microtubule Human genes 0.000 claims 1
- 108091022875 Microtubule Proteins 0.000 claims 1
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 claims 1
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 claims 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 claims 1
- 108090000854 Oxidoreductases Proteins 0.000 claims 1
- 102000004316 Oxidoreductases Human genes 0.000 claims 1
- 108010055723 PDGF receptor tyrosine kinase Proteins 0.000 claims 1
- MFOCDFTXLCYLKU-CMPLNLGQSA-N Phendimetrazine Chemical compound O1CCN(C)[C@@H](C)[C@@H]1C1=CC=CC=C1 MFOCDFTXLCYLKU-CMPLNLGQSA-N 0.000 claims 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims 1
- 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 claims 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 1
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 claims 1
- 229940083324 Selective androgen receptor modulator Drugs 0.000 claims 1
- 229940122388 Thrombin inhibitor Drugs 0.000 claims 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 claims 1
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 claims 1
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 229960002632 acarbose Drugs 0.000 claims 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 claims 1
- 229960002122 acebutolol Drugs 0.000 claims 1
- GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 229960002478 aldosterone Drugs 0.000 claims 1
- 229960004601 aliskiren Drugs 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 claims 1
- 229960002576 amiloride Drugs 0.000 claims 1
- 229960000528 amlodipine Drugs 0.000 claims 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 claims 1
- 229940025084 amphetamine Drugs 0.000 claims 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 230000003178 anti-diabetic effect Effects 0.000 claims 1
- 229940046836 anti-estrogen Drugs 0.000 claims 1
- 230000001833 anti-estrogenic effect Effects 0.000 claims 1
- 230000003579 anti-obesity Effects 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229940127088 antihypertensive drug Drugs 0.000 claims 1
- 239000003524 antilipemic agent Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000002814 antineoplastic antimetabolite Substances 0.000 claims 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 claims 1
- 229940127218 antiplatelet drug Drugs 0.000 claims 1
- 230000036528 appetite Effects 0.000 claims 1
- 235000019789 appetite Nutrition 0.000 claims 1
- 239000003886 aromatase inhibitor Substances 0.000 claims 1
- 229940046844 aromatase inhibitors Drugs 0.000 claims 1
- 229960002274 atenolol Drugs 0.000 claims 1
- 230000036523 atherogenesis Effects 0.000 claims 1
- 229960005370 atorvastatin Drugs 0.000 claims 1
- 229960004530 benazepril Drugs 0.000 claims 1
- YXKTVDFXDRQTKV-HNNXBMFYSA-N benzphetamine Chemical compound C([C@H](C)N(C)CC=1C=CC=CC=1)C1=CC=CC=C1 YXKTVDFXDRQTKV-HNNXBMFYSA-N 0.000 claims 1
- 229960002837 benzphetamine Drugs 0.000 claims 1
- UIEATEWHFDRYRU-UHFFFAOYSA-N bepridil Chemical compound C1CCCN1C(COCC(C)C)CN(C=1C=CC=CC=1)CC1=CC=CC=C1 UIEATEWHFDRYRU-UHFFFAOYSA-N 0.000 claims 1
- 229960003665 bepridil Drugs 0.000 claims 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims 1
- 229960004324 betaxolol Drugs 0.000 claims 1
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 150000004283 biguanides Chemical class 0.000 claims 1
- 229960002781 bisoprolol Drugs 0.000 claims 1
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 claims 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims 1
- 229960002802 bromocriptine Drugs 0.000 claims 1
- 229960001058 bupropion Drugs 0.000 claims 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 229960000932 candesartan Drugs 0.000 claims 1
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 claims 1
- 239000003536 cannabinoid receptor antagonist Substances 0.000 claims 1
- 229960000830 captopril Drugs 0.000 claims 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims 1
- 239000000496 cardiotonic agent Substances 0.000 claims 1
- 230000003177 cardiotonic effect Effects 0.000 claims 1
- 229960005110 cerivastatin Drugs 0.000 claims 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims 1
- GPUADMRJQVPIAS-QCVDVZFFSA-M cerivastatin sodium Chemical compound [Na+].COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 GPUADMRJQVPIAS-QCVDVZFFSA-M 0.000 claims 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 claims 1
- 230000001906 cholesterol absorption Effects 0.000 claims 1
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 claims 1
- 229960005132 cisapride Drugs 0.000 claims 1
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 claims 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims 1
- 229960003958 clopidogrel bisulfate Drugs 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 claims 1
- 229960004166 diltiazem Drugs 0.000 claims 1
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 229940030606 diuretics Drugs 0.000 claims 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 claims 1
- 229960001089 dobutamine Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229950009714 ecopipam Drugs 0.000 claims 1
- 229960000873 enalapril Drugs 0.000 claims 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims 1
- 229960002179 ephedrine Drugs 0.000 claims 1
- 229960001208 eplerenone Drugs 0.000 claims 1
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 claims 1
- 229940011871 estrogen Drugs 0.000 claims 1
- 239000000262 estrogen Substances 0.000 claims 1
- 239000000328 estrogen antagonist Substances 0.000 claims 1
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 claims 1
- 229960003199 etacrynic acid Drugs 0.000 claims 1
- 229960001519 exenatide Drugs 0.000 claims 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 claims 1
- 229950011548 fadrozole Drugs 0.000 claims 1
- 229960003580 felodipine Drugs 0.000 claims 1
- 229940087476 femara Drugs 0.000 claims 1
- 229960001582 fenfluramine Drugs 0.000 claims 1
- 229940125753 fibrate Drugs 0.000 claims 1
- 229960002464 fluoxetine Drugs 0.000 claims 1
- 229960002490 fosinopril Drugs 0.000 claims 1
- 229960003883 furosemide Drugs 0.000 claims 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 1
- 229960004580 glibenclamide Drugs 0.000 claims 1
- 229960001381 glipizide Drugs 0.000 claims 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims 1
- 230000002641 glycemic effect Effects 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 229960002003 hydrochlorothiazide Drugs 0.000 claims 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 1
- 229960002411 imatinib Drugs 0.000 claims 1
- 229960002198 irbesartan Drugs 0.000 claims 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims 1
- 229940039781 leptin Drugs 0.000 claims 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims 1
- 229960002394 lisinopril Drugs 0.000 claims 1
- CZRQXSDBMCMPNJ-ZUIPZQNBSA-N lisinopril dihydrate Chemical compound O.O.C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 CZRQXSDBMCMPNJ-ZUIPZQNBSA-N 0.000 claims 1
- 230000007774 longterm Effects 0.000 claims 1
- 239000002171 loop diuretic Substances 0.000 claims 1
- 229960004773 losartan Drugs 0.000 claims 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims 1
- 229960004844 lovastatin Drugs 0.000 claims 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 229960000299 mazindol Drugs 0.000 claims 1
- 229950004994 meglitinide Drugs 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 1
- 229960003105 metformin Drugs 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 229960002237 metoprolol Drugs 0.000 claims 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 claims 1
- 229950009116 mevastatin Drugs 0.000 claims 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 claims 1
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 claims 1
- 210000004688 microtubule Anatomy 0.000 claims 1
- PZRHRDRVRGEVNW-UHFFFAOYSA-N milrinone Chemical compound N1C(=O)C(C#N)=CC(C=2C=CN=CC=2)=C1C PZRHRDRVRGEVNW-UHFFFAOYSA-N 0.000 claims 1
- 229960003574 milrinone Drugs 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 230000004220 muscle function Effects 0.000 claims 1
- 229960004255 nadolol Drugs 0.000 claims 1
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 claims 1
- 229960000698 nateglinide Drugs 0.000 claims 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 claims 1
- 229960001783 nicardipine Drugs 0.000 claims 1
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- 229960001597 nifedipine Drugs 0.000 claims 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims 1
- 229960000715 nimodipine Drugs 0.000 claims 1
- 229960000227 nisoldipine Drugs 0.000 claims 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 claims 1
- 229960001243 orlistat Drugs 0.000 claims 1
- 229960000436 phendimetrazine Drugs 0.000 claims 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 claims 1
- 229960000395 phenylpropanolamine Drugs 0.000 claims 1
- 229960005095 pioglitazone Drugs 0.000 claims 1
- 229960002797 pitavastatin Drugs 0.000 claims 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims 1
- 150000003058 platinum compounds Chemical class 0.000 claims 1
- 229960002965 pravastatin Drugs 0.000 claims 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229960003387 progesterone Drugs 0.000 claims 1
- 239000000186 progesterone Substances 0.000 claims 1
- NPUSXSOBPNHOPH-UHFFFAOYSA-N propan-2-yl 4-(2-chlorophenyl)-1-ethyl-2-methyl-5-oxo-4,7-dihydrofuro[3,4-b]pyridine-3-carboxylate Chemical compound CC(C)OC(=O)C1=C(C)N(CC)C(COC2=O)=C2C1C1=CC=CC=C1Cl NPUSXSOBPNHOPH-UHFFFAOYSA-N 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 229960003712 propranolol Drugs 0.000 claims 1
- 230000004952 protein activity Effects 0.000 claims 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 claims 1
- 229960003908 pseudoephedrine Drugs 0.000 claims 1
- 229960001455 quinapril Drugs 0.000 claims 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 claims 1
- 229960003401 ramipril Drugs 0.000 claims 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 239000002461 renin inhibitor Substances 0.000 claims 1
- 229940086526 renin-inhibitors Drugs 0.000 claims 1
- 229960002354 repaglinide Drugs 0.000 claims 1
- 229960004586 rosiglitazone Drugs 0.000 claims 1
- 229960000672 rosuvastatin Drugs 0.000 claims 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 1
- 229960004937 saxagliptin Drugs 0.000 claims 1
- 108010033693 saxagliptin Proteins 0.000 claims 1
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 claims 1
- 239000000849 selective androgen receptor modulator Substances 0.000 claims 1
- 229940095743 selective estrogen receptor modulator Drugs 0.000 claims 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 claims 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 claims 1
- 229960004425 sibutramine Drugs 0.000 claims 1
- 229960002855 simvastatin Drugs 0.000 claims 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 1
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 claims 1
- 229960004034 sitagliptin Drugs 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 229960002370 sotalol Drugs 0.000 claims 1
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 claims 1
- 239000004059 squalene synthase inhibitor Substances 0.000 claims 1
- 229960005187 telmisartan Drugs 0.000 claims 1
- 229960003604 testosterone Drugs 0.000 claims 1
- 229940083085 thiazide derivative acting on arteriolar smooth muscle Drugs 0.000 claims 1
- LJJKNPQAGWVLDQ-SNVBAGLBSA-N thiorphan Chemical compound OC(=O)CNC(=O)[C@@H](CS)CC1=CC=CC=C1 LJJKNPQAGWVLDQ-SNVBAGLBSA-N 0.000 claims 1
- 239000003868 thrombin inhibitor Substances 0.000 claims 1
- 229960004605 timolol Drugs 0.000 claims 1
- 229960004394 topiramate Drugs 0.000 claims 1
- 229960005461 torasemide Drugs 0.000 claims 1
- 229960002051 trandolapril Drugs 0.000 claims 1
- 229960001722 verapamil Drugs 0.000 claims 1
- 229960001254 vildagliptin Drugs 0.000 claims 1
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 claims 1
- ZXIBCJHYVWYIKI-PZJWPPBQSA-N ximelagatran Chemical compound C1([C@@H](NCC(=O)OCC)C(=O)N2[C@@H](CC2)C(=O)NCC=2C=CC(=CC=2)C(\N)=N\O)CCCCC1 ZXIBCJHYVWYIKI-PZJWPPBQSA-N 0.000 claims 1
- 229960001522 ximelagatran Drugs 0.000 claims 1
- 229940051223 zetia Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64996205P | 2005-02-03 | 2005-02-03 | |
| PCT/US2006/003924 WO2006084176A2 (en) | 2005-02-03 | 2006-02-03 | Compounds and compositions as ppar modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008528700A JP2008528700A (ja) | 2008-07-31 |
| JP2008528700A5 true JP2008528700A5 (enExample) | 2008-10-09 |
Family
ID=36777985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007554257A Pending JP2008528700A (ja) | 2005-02-03 | 2006-02-03 | Ｐｐａｒモジュレーターとしての化合物および組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7750032B2 (enExample) |
| EP (1) | EP1843763A2 (enExample) |
| JP (1) | JP2008528700A (enExample) |
| KR (1) | KR100929069B1 (enExample) |
| CN (1) | CN101141957A (enExample) |
| AU (1) | AU2006210503B2 (enExample) |
| CA (1) | CA2595789A1 (enExample) |
| MX (1) | MX2007009356A (enExample) |
| RU (1) | RU2007132973A (enExample) |
| WO (1) | WO2006084176A2 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0715160A2 (pt) | 2006-08-08 | 2013-06-11 | Sanofi Aventis | imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso |
| UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE102007054497B3 (de) | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung |
| US8470841B2 (en) | 2008-07-09 | 2013-06-25 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| ES2443016T3 (es) | 2009-08-26 | 2014-02-17 | Sanofi | Nuevos hidratos cristalinos de fluoroglicósidos heteroaromáticos, productos farmacéuticos que comprenden estos compuestos, y su empleo |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| WO2012030165A2 (ko) | 2010-08-31 | 2012-03-08 | 서울대학교산학협력단 | P P A R δ 활성물질의 태자재프로그래밍용도 |
| EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2799542A4 (en) * | 2011-12-29 | 2015-07-01 | Tao Health Life Pharma Co Ltd | A TARGET MOLECULE WITH AMYLOSPHEROID BINDING FOR INDUCING NEURONAL CELL DEOD, METHOD AND MEANS FOR INHIBITING AMYLOSPHEROID-INDUCED NEURONAL CELL DEOD AND APPLICATIONS THEREOF AND METHOD AND METHOD THEREFOR |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| MX382630B (es) | 2016-04-29 | 2025-03-13 | Fgh Biotech Inc | Compuestos de pirazol disustituidos para el tratamiento de enfermedades. |
| EP3510027B1 (en) * | 2016-09-07 | 2022-11-02 | FGH BioTech, Inc. | Di-substituted pyrazole compounds for the treatment of diseases |
| US10927094B2 (en) * | 2016-10-05 | 2021-02-23 | Mitobridge, Inc. | Crystalline and salt forms of PPAR agonist compounds |
| CN112040953A (zh) * | 2018-03-09 | 2020-12-04 | 布赖汉姆妇女医院 | 用于心血管疾病的组合治疗 |
| CN113527269A (zh) * | 2020-04-17 | 2021-10-22 | 上海京新生物医药有限公司 | 一种匹伐他汀钙氧化杂质的制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6613789B2 (en) * | 1994-07-28 | 2003-09-02 | G. D. Searle & Co. | Heterocyclo-substituted imidazoles for the treatment of inflammation |
| US5616601A (en) * | 1994-07-28 | 1997-04-01 | Gd Searle & Co | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation |
| US6350892B1 (en) * | 1997-09-23 | 2002-02-26 | Bristol-Myers Squibb Company | Trifluoromethyl ketone analogs as selective cPLA2 inhibitors |
| HN2002000266A (es) * | 2001-09-24 | 2003-11-16 | Bayer Corp | Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad. |
| WO2003062252A1 (en) * | 2002-01-18 | 2003-07-31 | Merck & Co., Inc. | Edg receptor agonists |
| AU2004311909A1 (en) * | 2003-12-22 | 2005-07-21 | Eli Lilly And Company | Triazole, oxadiazole and thiadiazole derivative as PPAR modulators for the treatment of diabetes |
-
2006
- 2006-02-03 RU RU2007132973/04A patent/RU2007132973A/ru not_active Application Discontinuation
- 2006-02-03 AU AU2006210503A patent/AU2006210503B2/en not_active Ceased
- 2006-02-03 CA CA002595789A patent/CA2595789A1/en not_active Abandoned
- 2006-02-03 EP EP06734339A patent/EP1843763A2/en not_active Withdrawn
- 2006-02-03 MX MX2007009356A patent/MX2007009356A/es not_active Application Discontinuation
- 2006-02-03 KR KR1020077019990A patent/KR100929069B1/ko not_active Expired - Fee Related
- 2006-02-03 JP JP2007554257A patent/JP2008528700A/ja active Pending
- 2006-02-03 WO PCT/US2006/003924 patent/WO2006084176A2/en not_active Ceased
- 2006-02-03 US US11/815,096 patent/US7750032B2/en not_active Expired - Fee Related
- 2006-02-03 CN CNA2006800067679A patent/CN101141957A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008528700A5 (enExample) | ||
| RU2008135128A (ru) | Производные спироимидазола в качестве модуляторов ppar | |
| RU2007132973A (ru) | Соединения и композиции в качестве модуляторов ppar | |
| RU2008135126A (ru) | Полициклические производные тетрагидроизохинолина и содержащие их композиции в качестве модуляторов ppar | |
| RU2008135125A (ru) | Соединения и композиции в качестве модуляторов ppar | |
| JP2007537286A5 (enExample) | ||
| RU2006145894A (ru) | Соединения и композиции, как модуляторы активированных рецепторов пролифератора пероксисомы | |
| RU2006144124A (ru) | Соединения и композиции в качестве модуляторов ppar-рецепторов, активируемых пролифератором пероксисом | |
| RU2006145893A (ru) | Соединения и композиции, как модуляторы активированных рецепторов пролифератора периксисомы | |
| US9670193B2 (en) | Trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease | |
| KR101616133B1 (ko) | Ｄｇａｔ１ 억제제로서의 옥사디아졸- 및 옥사졸-치환된 벤즈이미다졸- 및 인돌-유도체 | |
| US10538502B2 (en) | Tricyclic spiro compound | |
| US20070191371A1 (en) | Heterocyclic modulators of ppar | |
| RU2006144121A (ru) | Соединения и композиции в качестве модуляторов ppar рецепторов, активируемых пролифератором пероксисом | |
| JP2010515715A5 (enExample) | ||
| RU2008122547A (ru) | Соединения и композиции как модуляторы арпп (активированных рецепторов пролифератора пероксисом) | |
| CA2674436A1 (en) | Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors | |
| JP2015533157A (ja) | ［オルトビ−（ヘテロ−）アリール］−［２−（メタビ−（ヘテロ−）アリール）−ピロリジン−１−イル］−メタノン誘導体であるオレキシン受容体アンタゴニスト | |
| RU2008122548A (ru) | Соединения и композиции, как модуляторы арпп (активированных рецепторов пролифератора пероксисом) | |
| US11479550B2 (en) | EP4 antagonist | |
| JP2007537287A5 (enExample) | ||
| RU2008122546A (ru) | Оксазоловый и тиазоловый модулятор арпп (активированных рецепторов пролифератора пероксисом) | |
| CN104995188B (zh) | 2-((1r,4r)-4-(4-(5-(苯并噁唑-2-基氨基)吡啶-2-基)苯基)环己基)乙酸的葡甲胺盐形式和它们作为dgat1抑制剂的用途 | |
| ZA200608731B (en) | Compounds and compositions as PPAR modulators | |
| JP2012505225A5 (enExample) |